ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa...
Continue Reading-
Hadean Ventures announces oversubscribed final close of Hadean Capital II
Hadean Ventures announces oversubscribed final close of Hadean Capital II
Continue Reading -
Ribbon Biolabs appoints Jodi Barrientos Chief Executive Officer
Ribbon Biolabs appoints Jodi Barrientos Chief Executive Officer; Founder Harold De Vladar named an advisor…
Continue Reading -
Complement Therapeutics Enrols First US Participant
Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with…
Continue Reading -
Abliva Achieves Important Milestone in the Ongoing FALCON Study
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare…
Continue Reading -
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation Abliva AB (Nasdaq Stockholm: ABLI) a…
Continue Reading -
ARTHEx Biotech Announces Closing of €42 M Series B Financing
ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel…
Continue Reading -
Complement Therapeutics Secures €72 Million in Series A Financing
Complement Therapeutics Secures €72 Million in Series A Financing...
Continue Reading -
Alex Therapeutics extends financing round to €4.75M with leading life science VC
Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital…
Continue Reading -
Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™
Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…
Continue Reading